US Stock MarketDetailed Quotes

RVNC Revance Therapeutics

Watchlist
  • 3.530
  • +0.580+19.66%
Close Aug 9 16:00 ET
  • 3.500
  • -0.030-0.85%
Post 17:39 ET
370.03MMarket Cap-1096P/E (TTM)

Revance Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Revance Therapeutics Earnings Date

Currency: USD

Period

Q2 FY2024 Earnings

Aug 8, 2024

Revenue(YoY)

65.39M

+20.17%
EPS(YoY)

-0.36

+55.00%
Analyst Rating

Buy

Aug 9, 2024

Revance Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 87.561M--
--2024/Q3-- / 67.490M--
Aug 8, 20242024/Q265.389M / 66.290M--
May 9, 20242024/Q151.936M / 56.658M--
Feb 28, 20242023/Q469.799M / 62.098M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 87.561M--
--2024/Q3-- / 67.490M--
Aug 8, 20242024/Q265.389M / 66.290M--
May 9, 20242024/Q151.936M / 56.658M--
Feb 28, 20242023/Q469.799M / 62.098M--

Unlock Free Earnings Estimates

Revance Therapeutics Earnings Reports

  • Revance Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8 16:40 ET

  • Revance Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 9 16:42 ET

  • Revance Therapeutics | 10-K: FY2023 Annual Report

    Feb 28 22:37 ET

  • Revance Therapeutics: Q3 2023 Earnings Report

    Nov 8, 2023 16:33 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 9, 2024

    Buy

    • Buy

      71.43%

    • Hold

      28.57%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg